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Rashid Mehmood1*, Kazuya Jibiki2, Zakeya J. Alsafwani1, Muhammad Naseem3, Noriko Yasuhara2*

Abstract

B

ackground: Nucleoporins (Nups) constitute a large group of proteins that are structurally
arranged at the nuclear envelope and facilitate the bidirectional movement of molecules across
the nuclear membrane. In addition to regulating the shuttling of ribonucleoprotein complexes,
RNAs and proteins, various Nups interact with chromatin either directly or indirectly, thus regulating
gene expression. Any mutations or expression anomalies of Nups may lead to abnormal localization of
critical molecules, or dysregulated expression of genes that they interact with. A comprehensive
genomic study encompassing all Nup genes in relation to breast cancer is lacking.
Methods: We used genomic and transcriptomic datasets from Pan-Cancer TCGA (The Cancer Genome
Atlas), Genotype-Tissue Expression (GTEx) and microarray platforms and conducted in silico analysis of
all the genes encoding nucleoporins that are associated with the Nuclear Pore Complexes (NPCs). For
mutation detection, we used cBioportal; for expression analysis, we used Xena and for patient survival
plots, KMPlot was utilized.
Results: The genetic and molecular profile of nucleoporin genes identified multiple mutations and
detected aberrant expression in breast cancer. Interestingly, NUP133, AHCTF1, TPR, Nup121L showed
simultaneous gene amplification in nearly 10% of breast cancer patients. In addition, deregulated
expression of some of the nucleoporins, namely, NUP62, NUP 93, NUP98, NUP155, POM121L12, RAE1,
SEC13, TPR were correlated with patient prognosis.
Conclusion: The current study is the first one that unravels a comprehensive molecular and genetic
profile of nucleoporins genes in breast cancer and underscores the critical roles of various nucleoporins
in cancer progression. The identified molecules may advance our understanding of the etiology of the
disease and serve as possible targets for novel therapeutic strategies in cancer.

Keywords:
Nuclear Pore Complexes
(NPCs); Nucleoporins; Breast
cancer; Bioinformatics
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Nuclear pore complexes (NPCs), embedded in the
nuclear envelope, provide a gateway for the movement
of molecules in and out of the nucleus. The barrier
function of the nuclear envelope is quintessential not
only for maintaining the distinct composition of the
nucleus but also for the unique functions therein. Two
types of movements take place through the NPCs;
passive diffusion that involves movements of small
sized proteins, metabolites, and ions, and facilitative
transport
wherein
large
molecules
including
ribonucleoprotein complexes, RNAs and proteins cross
the nuclear envelope. The facilitative transport requires
particular transport receptors, called importins and
exportins. Both of these types of transport are mediated
by the NPCs [1]. NPCs are megadalton complexes
(approximately 60-125MDa) and are composed of ~30
distinct proteins called nucleoporins (Nups), which
provide binding sites for transport receptors for the
transport of molecules in and out of the nucleus [2].
The NPCs are remarkably complicated structures and
are composed of three structurally distinct regions. 1)
the cytoplasmic ring from which filaments extend into
the cytoplasm, 2) the nuclear basket that extends to the
nucleoplasmic faces of the NPCs and, 3) the central
framework which makes up the pore [3]. The correct
positioning of various Nups in the NPC warrants their
structural and functional roles, facilitating the transport
of selective molecules [4]. The NPC assembly requires
coordination between NUPs. For instance, Nup133, a
component of the NPC scaffold, is required for Tpr and
Nup153 assembly into the nuclear basket. For the
transport of molecules into the nucleus, the
karyopherins that bind NLS (Nuclear Localization
Signal) containing cargoes interact with FG (Phe-Gly)
repeats containing Nups of the NPCs and mediate the
translocation of the transport complex [5]. Once into the
nucleus, the association between Nups and importins is
disengaged by the action of RanGTP by virtue of its very
high binding affinity to importins [6]. Conversely, the
nuclear export of a number of proteins is mediated by
interaction of Exportins with RanGTP, while RanGTP
independent export also exist, as in case of mRNAs [7].
In addition to their well-known role in the transport of
molecules across the nuclear membrane, some of the
Nups have been shown to regulate a variety of functions,
including RNA processing, transcriptional activation,
and chromatin modulation [8-10]. Their widespread
functions are strengthened by the fact that some NUPs
(i.e. NUP98, NUP62, NUP50, NUP153) are not only
localized to the NPCs; instead, they exhibit dynamic
features by moving off and on of the NPCs. Their
shuttling in and out of the nucleus and interaction with
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cytosolic and nuclear components point to their
unorthodox functions. An interesting correlation was
found between the expression levels of genes and their
position in the vicinity of the NPCs [11]. The observation
that the genomic regions nearby the NPCs are
transcriptionally active led to the identification of their
roles in transcriptional regulation [12, 13]. NUP53, for
instance, was shown to not only bind DNA, but its
binding pattern was co-enriched with other
transcriptional activation markers, i.e., Histone H4K16
acetylation and RNA polymerase II [14]. Over the years,
the roles of a battery of Nups were identified in
regulating the chromatin landscape [15]. A subset of the
Nups regulate expression of genes implicated in cellular
identity thus regulating cellular differentiation and
development [16, 17]. Moreover, recently, their roles in
viral infection and innate immunity is also described
[85, 86]. Therefore, it is not surprising that aberrant
expression patterns of various Nups are associated with
a wide range of medical conditions [18, 19].
Genomic fusions involving Nups with other partners
have been found in hematopoietic and nonhematopoietic malignancies [20, 21]. Additionally, the
deregulated expression and mutations of some Nups are
also linked with various cancers [22, 23]. Their roles in
cancer progression may be due to specifically expediting
the nuclear translocation of oncogenes, e.g., E2F1, MYC,
thus enhancing their oncogenic activities [24] or
through interacting with chromatin, thus regulating
chromatin remodeling, and regulating the transcription
of genes [25]. In breast cancer, only few studies have
looked into the individual Nups for their roles in cellular
transformation. NUP88 mRNA overexpression, for
instance, has been shown to be associated with high
aggressiveness of breast cancer [26]. Inverse correlation
of NUP93 expression with the survival of triple-negative
breast cancer patients by modulating cytoskeleton
remodeling has been recently shown [27]. However, to
our knowledge, a comprehensive study of all the
nucleoporins cataloging their mutational profile,
differential expression compared with the normal tissue
and their correlation with breast cancer patient survival
is lacking. In the current study, using genomic and
transcriptomic datasets from The Cancer Genomic Atlas
(TCGA) and microarray platforms, we analyzed all the
known genes encoding components of NPCs in breast
cancer. Our data suggest that majority of NUPs are
mutated/aberrantly expressed in breast cancer, albeit
with varying degrees, and point to the implications of
NUPS in patients’ prognosis.

Methods

Genetic alterations in Nup genes
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In order to identify mutations in various Nups, we
utilized TCGA (The Cancer Genome Atlas) data using
cBioportal [28 ,29]. At the cBioportal, breast cancer
datasets are available from multiple sources. We
selected the latest TCGA Breast Invasive Carcinoma
(Firehouse legacy). In this category, there are 963
patients that had both mutation and CNA (Copy number
alterations) data. Therefore, following genetic
alterations were scanned in these 963 breast cancer
patients' datasets; 1) Mutations, 2) CNA (copy number
alterations). Ethical approval was not needed for the
study as all datasets in this study were utilized from
public databases (TCGA), and processing of data were
according to the TCGA publication guidelines
(https://cancergenome.nih.gov/publications/guidelines
).
Nups and encoding genes nomenclature
Nucleoporins constitute all the proteins that make up
the nuclear pore complexes. However, before their
identification as a part of this huge nuclear pore
complexes, they adapted different names based on
interacting proteins and functions they were associated
with. For the sake of consistency, we used Human
Genome Organization (HUGO) gene nomenclature
committee resource (https://www.genenames.org/). All
the genes corresponding to nucleoporins were identified
from this HUGO resource and published literature [30].
The list of Nups encoded by respective genes are listed
in Table 1.
NUPs Interactome and network analysis
We mapped protein-protein interactions among NUPs
specific proteins as high confidence interactome
retrieved from STRING database (https://string-db.org/)
[87]. The list of NUPs genes (tables 1) was given as input
identifiers to the muti-proteins search option of the
STRING database. A stringent criterion for the selection
of interactions as combined edge score greater than 0.9
(P-values for Bayesian confidence score) resulted in a
densely connected network, composed of 35 nodes and
175 edges. For network analysis we used STRING inbuilt
analysis function for degree and clustering co-efficient.
We only selected experimental interactions and
visualized the network in evidence mode as STRING
output. The edges denote both functional and physical
protein associations among the nodes as opted in the
basic settings options.
Gene expression changes compared with the normal
tissue
For expression comparison between normal tissue and
breast cancer samples, we used Xena [67] which
incorporates data from TCGA datasets and GTEX for
comparison between the two [68].
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The gene list in the table 1 was used to generate heat
map. All the genes were incorporated in the UCSC Xena.
After launching Xena, the first variable phenotype
“main category” was selected. In the second Genomic
variable, Gene expression was chosen, followed by
incorporating all the genes encoding Nups. TCGA GTEX
datasets was used to generate heatmap. Additionally,
box plots for the individual genes were fetched from the
“view chart” to make gene expression comparisons
between GTEX and TCGA breast cancer patients'
datasets. As Xena utilizes the same pipeline for TCGA
and GTEx samples, therefore, both datasets are reanalyzed (using UCSC Toil RNA-seq recompute
compendium) to eliminate batch effects [67].
Patient survival plots
Kaplan-Meier Plotter was used to generate MeierKaplan plots wherein multiple microarray expression
datasets are incorporated from 7462 breast cancer
patients [69]. In order to generate overall survival plots,
the patients were split by median. For the best probe
selection, “jetset” was selected for the shown time
periods. The indicated p value does not include
correction for multiple hypothesis testing by default
[69].

Results

Mutational landscape of various Nups in breast
cancer
In order to delineate the roles of nuclear transport
process in breast cancer progression, we recently carried
out bioinformatic analysis of TCGA datasets and showed
that various genes encoding factors related to nuclear
transport are mutated [70]. An equally important aspect
of the nuclear transport process is the interaction of
transport factors with the components of the NPCs and
subsequent translocation to the nucleus. Therefore,
mutations in the genes coding for Nups, the proteins
that constitute the NPCs, may disrupt/expedite the
nuclear transport process. Thus, it is imperative to
identify various mutations in this category of genes.
Therefore, using TCGA datasets, we characterized
mutations in Nup genes and found that majority of the
Nup genes were genetically altered in breast cancer
patients. The alteration frequency differed markedly
(ranging from 0.4% in AAAS to 15% in AHCTF1) (Figure
1) amongst various Nups. Interestingly, gene
amplification appeared to be the most prevalent genetic
anomaly. Additional mutations were also detected,
including deep deletions, base substitutions and
multiple alterations. A synergistic gene amplification in
AHCTF1, NUP133, NUP210L and TPR was found in over
10% of patients. Figure 1B shows the frequency of
mutations in the components of nuclear envelope based
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on their location in the nuclear pore. To further expand
on the possible consequences of genetic alterations on
the nuclear pore architecture and to get functional
insights into the NUPs genes, we mapped physical
interactions among their encoded proteins. A densely
connected network of NUPs proteins was derived from
the publicly available STRING database [87]. As shown
in the Figure 1C, there are 35 protein nodes in the
network that constitute 175 edges with diverse
functional implications. Interactions between Nup133,
AHCTF1 and Nup210L, that are synergistically
amplified, are clearly visible in the interactome.
Interestingly, alteration frequency in all Nup genes was
found to be in nearly 50% of the patients representing
significance of this set of molecules (Supplementary
figure 1A). Genetic alterations in Nups genes were
detected in all breast cancer subtypes albeit with
variable rates and types of genetic alterations. In order
to validate our analysis, we used PIK3CA, TP53, CDH1,
and GATA3. Consistent with literature, we found high
prevalence of mutations in these control genes (Figure
1A).
After establishing that Nup genes are mutated in
breast cancer, we stratified breast cancer patients into
metaplastic breast cancer, breast invasive ductal
carcinoma, breast mixed ductal and lobular carcinoma,
breast invasive locular carcinoma, and breast invasive
mixed mucinous carcinoma and looked for mutations
(Supplementary figure 1B). Additional analysis also
identified co-occurrences and mutual exclusivities of
these top mutated genes with several Nups (Table 2).
The frequency of genetic alterations was not specific to
breast cancer. We utilized TCGA PanCancer Atlas
Studies that has datasets from a variety of cancers and
identified similar trends in mutations in majority of the
cancers. This shows that mutations in Nup genes span a
spectrum of cancers (Figure 2).
Nups related genes undergo massive expression
anomalies in breast cancer
Recent transcriptomic analysis showed massive
transcriptomic deregulation is an important hallmark of
cancer. A number of genes are not only aberrantly
expressed in breast cancer, but may also serve as
biomarkers. Therefore, we analyzed RNA levels of all
Nup genes compared with the normal tissue. The cancer
patient’s data was from TCGA, and for comparison GTEx
datasets were used. As can be seen in Figure 3A, several
Nup genes showed deregulated expression in breast
cancer. In majority of the genes analyzed,
overexpression was detected to be major anomaly in
cancer patients compared with the samples from GTEx.
However, a few genes including AAAS, POM121, and
DDX19B showed reduced expression in cancer patients
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compared with the GTEx cohort. The high expression in
TCGA datasets might be associated with high
amplification rate, at least partially. Figure 3B shows
comparisons of individual gene expression between
TCGA and GTEx datasets. Collectively, majority of genes
encoding Nups go through massive deregulation in
expression in cancer patients.
Nups with correlation with patient overall survival.
Having established that genetic aberrations and
expression changes in cancer patients prevail
significantly, next was to determine if any of these
changes in gene expression in Nups have a prognostic
potential. Mining various microarray datasets using
Meier-Kaplan (KM) Plotter [69], we calculated overall
survival (OS) of breast cancer patients based on
expression of Nup genes. Out of all the Nup genes
tested, NUP62, NUP93, RAE1, NUP155, and SEC13
overexpression showed poor overall survival, while
POM121L12, TPR, and NUP98 overexpression were
correlated with better patient survival. TOP2A, a wellknown marker for poor patient survival is also shown in
the figure 4, which, consistent with its established role,
showed poor patient OS. All other Nups that did not
show any significant correlation with patient overall
survival are shown in Supplementary figure 2. Overall,
the analysis identifies several molecules that might have
prognostic potential in breast cancer.

Discussion
In this study, we describe a comprehensive genetic and
molecular landscape of nucleoporins genes in breast
cancer. Our analysis shows that a number of Nup genes
are not only mutated but also undergo drastic
expression changes in breast cancer.
Among the Nup genes, we found that AHCTF1,
NUP133, NUP210L and TPR were synergistically altered
in around 10% of patients. Nup133 is located in the NPC
scaffold forming the Y-complex together with Nup85,
SEC13, Nup160, Nup107 [88]. It has been shown that
Nup133 is instrumental in formation of the nuclear
basket with its role in the Tpr and Nup153 recruitment
to the NPC basket [89]. Moreover, Tpr is necessary for
the nuclear export of mRNAs and proteins. Thus, if the
gene products of NUP133 and TPR genes are
synergistically altered, the assembly and the functions
of NPC could be significantly altered. AHCTF1, also
known as ELYS, is not only necessary for post-mitotic
NPC assembly through recruitment of chromatin but
also regulates the nuclear size [90]. Therefore,
simultaneous changes in the quality and quantity of
these NUPs could have a significant impact on the
function of the nuclear pores, which may define the
behavior of cancer.
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Figure 1
A

B

(963 patients)

C

Figure 1: Genes encoding nucleoporins are genetically altered in breast cancer. (A) Various genetic alterations in nucleoporins
are detected in breast cancer. Lines in the horizontal bars represent 963 breast cancer patients. Different color schemes in the
figure represent amplification, deep deletion, in frame mutation, missense mutation and truncating mutations. The most
prevalent genetic alteration detected among the nuclear transport family is the amplification. As positive controls, PIK3CA, TP53,
CDH1 and GATA3 are used. (B) Mapping of NUP mutations in the NPC structure. The approximate positions of proteins and the
mutation rate in colors are shown. (C) Mapping of NUPs specific interactome and network based topological insight. The round
shapes are nodes with miniature NUPs protein structures in the spheres. The number of nodes of the network are 35, while
straight lines are directionless (175) edges in the network. The average node degree of the network is 10, while the avg. local
Figure
2 the PPI enrichment p-value: < 1.0e-16. The network has significantly more interactions than
clustering coefficient
is 0.699,
random network.

Figure 2: Genes encoding nucleoporins are mutated in a wide variety of cancers. TCGA PanCancer Atlas datasets were used to
identify spectrum of mutations in different cancer types. Querying 10953 patients / 10967 samples in 32 studies. Queried Nup
genes are altered in 4552 (42%) of queried samples.
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Figure 3: Comparison of expression of genes that encode nucleoporins. (A) Over/under expression of all the genes is represented
by red/blue bars respectively. The data from GTEx is used to compare the expression of normal breast tissue with breast cancer
samples from TCGA. TOP2A and CCND2 are used as controls. (B) Comparisons of individual Nup genes expression in normal vs
breast cancer patient samples. The p values for individual genes are calculated using Welch's t-test. NUP85-p = 2.391e-13 (t =
7.535), NUP160-p = 0.000004021 (t = -4.647), NUP107-p = 3.156e-20 (t = -9.694), NUP98-p = 1.599e-13 (t = -7.674), NUP133-p
= 6.677e-127 (t = -30.64), SEC13-p = 7.633e-80 (t = -24.77), SEH1L-p = 4.966e-46 (t = -16.36), NUP37-p = 1.090e-112 (t = -32.86),
NUP43-p = 1.143e-34 (t = -14.02), AHCTF1-p = 1.012e-15 (t = -8.435), NUPL2-p = 0.02267 (t = -2.287), RANBP2-p = 3.152e-47
(t = -15.70), NUP214-p = 0.001859 (t = -3.141), NUP88-p = 4.548e-20 (t = -9.647), AAAS-p = 0.000 (t = 15.51), GLE1-p = 2.849e131 (t = -38.31), NUP62-p = 1.600e-121 (t = -35.62), NUP62CL-p = 1.344e-25 (t = -11.73), RAE1-p = 8.397e-108 (t = -27.93),
NUP93-p = 5.991e-63 (t = -18.83), NUP188-p = 1.730e-30 (t = -12.67), NUP205-p = 8.034e-82 (t = -21.80), NUP35-p = 2.813e-17
(t = -9.110), NUP155-p = 1.007e-155 (t = -37.19), TPR-p = 1.705e-51 (t = -16.93), NUP153-p = 0.00005305 (t = -4.073), NUP50p = 5.891e-100 (t = -28.78), NDC1-p = 1.897e-168 (t = -45.57), NUP210-p = 3.468e-71 (t = -28.35), NUP210L-p = 0.0001713 (t =
3.825), POM121-p = 0.000 (t = 16.28), POM121L2-p = 0.06428 (t = 1.859), POM121L12-p = 0.005488 (t = 2.810), POM121C-p =
2.887e-15 (t = 8.203), NUPL1-p = 2.792e-18 (t = -9.235), NUP54-p = 0.7115 (t = 0.3700), DDX19B-p = 0.000 (t = 12.45).

Figure 4: Correlation of Nup genes with breast cancer patients over all survival. Expression of Nup genes correlate with over all
patient samples. Overall patient survival shown by Meier-Kaplan plots. X axis shows Overall survival percentage, and Y axis
shows Months after the diagnosis. High expression group is indicated by red, while the low expression group is shown by the
black color. The patients (n=1402) were split by median. p-values were determined using the Log-Rank test.
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Nucleoporin Protein Name
NUCLEOPORIN 85
NUCLEOPORIN 160
NUCLEOPORIN 107
NUCLEOPORIN 98/96
NUCLEOPORIN 133
SEC13
SEH1 LIKE NUCLEOPORIN
NUCLEOPORIN 37
NUCLEOPORIN 43
ELYS
NUCLEOPORIN 42
RAN BINDING PROTEIN 2
NUCLEOPORIN 214
NUCLEOPORIN 88
ALADIN WD REPEAT NUCLEOPORIN
GLE1
NUCLEOPORIN 62
NUCLEOPORIN 62 C-TERMINAL LIKE
RAE1
NUCLEOPORIN 93
NUCLEOPORIN 188
NUCLEOPORIN 205
NUCLEOPORIN 35
NUCLEOPORIN 155
TPR
NUCLEOPORIN 153
NUCLEOPORIN 50
NDC1
NUCLEOPORIN 210
NUCLEOPORIN 210L
POM121
POM121 transmembrane nucleoporin like 2
POM121 transmembrane nucleoporin like 12
POM121 transmembrane nucleoporin C
NUCLEOPORIN 58/45
NUCLEOPORIN 54
DDX19

Gene symbol
NUP85
NUP160
NUP107
NUP98
NUP133
SEC13
SEH1L
NUP37
NUP43
AHCTF1
NUPL2/NUP42
RANBP2
NUP214
NUP88
AAAS
GLE1
NUP62
NUP62CL
RAE1
NUP93
NUP188
NUP205
NUP35
NUP155
TPR
NUP153
NUP50
NDC1
NUP210
NUP210L
POM121
POM121L2
POM121L12
POM121C
NUPL1/NUP58
NUP54
DDX19B

Reference
[31]
[32]
[33]
[34, 35]
[32]
[36]
[37]
[38]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60]
[61]
[62]
[63]
[64]
[65]
[66]

Table 1: Various Nucleoporins (Nups) and genes encoding them.
A
NUP133

B
AHCTF1

Neither
801

A Not B
17

B Not A
35

Both
110

Log2 Odds Ratio
>3

p-Value
<0.001

q-Value
<0.001

Tendency
Co-occurrence

TPR
NUP133
AHCTF1
AHCTF1
NUP133
SEC13
NUP93
DDX19B
GLE1
TP53
NUP214
NUP153
POM121
NUP93

NUP210L
TPR
TPR
NUP210L
NUP210L
NUP210
DDX19B
CDH1
NUP188
CDH1
NUP188
POM121L2
POM121C
CDH1

805
798
783
773
785
937
934
831
940
540
936
924
931
826

37
55
70
69
57
9
10
3
9
294
13
23
23
8

48
38
35
45
51
5
8
113
7
116
7
8
3
116

73
72
75
76
70
12
11
16
7
13
7
8
6
13

>3
>3
>3
>3
>3
>3
>3
>3
>3
-2.280
>3
>3
>3
>3

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Mutual exclusivity
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence

NUP42
NUP214
PIK3CA
NUP153
SEC13
TPR
NUP133
NUP98
POM121L2
NUP85
NUP42
POM121
NUP42
NUP188
NUP85

POM121L12
GLE1
GATA3
TP53
NUP188
POM121
POM121C
NUP214
TP53
NUP155
NUP205
GATA3
PIK3CA
NUP210
RAE1

930
932
509
646
932
835
833
929
652
876
924
810
594
935
840

19
15
319
10
17
99
121
14
4
57
21
18
23
11
53

8
11
108
286
10
18
3
16
295
22
14
124
344
14
58

6
5
27
21
4
11
6
4
12
8
4
11
2
3
12

>3
>3
-1.326
2.246
>3
2.366
>3
>3
2.729
2.482
>3
1.997
-2.736
>3
1.713

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.001
0.001
0.001
0.002

<0.001
<0.001
<0.001
0.001
0.006
0.006
0.011
0.012
0.015
0.016
0.027
0.031
0.042
0.042
0.042

Co-occurrence
Co-occurrence
Mutual exclusivity
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence
Mutual exclusivity
Co-occurrence
Co-occurrence

NUP153
NUP85
SEC13
RAE1

POM121
SEC13
AHCTF1
TP53

908
883
806
620

26
59
12
36

24
15
136
273

5
6
9
34

2.863
2.582
2.152
1.101

0.002
0.002
0.002
0.002

0.045
0.045
0.045
0.045

Co-occurrence
Co-occurrence
Co-occurrence
Co-occurrence

Table 2: Mutual exclusivity cooccurrence
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We recently catalogued genetic and molecular
attributes of all the genes encoding nuclear transport
factors in breast cancer [70]. A crucial part of the nuclear
transport process is the interaction of Nups with the
actual transport receptors. Nups constitute a group of
proteins that constitute the nuclear pore complexes.
Their critical role in regulating transport of molecules
across the nuclear membrane is already established [71].
One of the categories of cargo that traverse through the
nuclear membrane is the proteins related to regulation
of cell cycle. Therefore, the functions of Nups in cell
cycle regulation become pivotal. Mislocalization of cell
cycle regulators has been linked to various cancers [24].
Our knowledge of individual Nups is rudimentary with
limited evidence of NUP43, NUP88 and NUP98 to be
drivers of breast cancer [72, 73].
However, an
overarching molecular profiling of Nup genes in cancer
was lacking. Our study fills this gap by providing
comprehensive analysis of all Nup genes in breast
cancer.
Most popular and known association of Nups with
various malignancies including leukemiac and non
leukemiac are through juxtaposition of nup genes with a
wide range of other genes [20, 21]. Nup98, for instance,
is frequently identified to be translocated with a number
of factors and mediate transcription changes depending
on its fusion partner [74]. However, there is little
knowledge regarding the role of individual Nups in
cancer progression. Their molecular analysis of
individual role of Nups is critical as they perform diverse
aspects of cell cycle either by regulating the
nucleocytoplasmic shuttling of various molecules
implicated in cancer or by direct or indirect interaction
with chromatin., thus regulating expression of genes
with possible implications with cancer. An evidence in
support of the first aspect was recently reported in
prostate cancer wherein overexpression of POM121 led
to enhanced nuclear import of E2F1, MYC, and AR,
eventually affecting tumorigenesis, proliferation, and
survival in lethal prostate cancer [24]. We identified
that, in breast cancer, several other Nups were either
mutated or had deregulated expression. Interestingly,
some of them are implicated in directing nuclear
transport by interacting with transport receptors [75],
implicating possible nuclear transport related functions.
In addition to above mentioned functions of Nups,
evidence regarding their un-expected role in
coordinating cell cycle regulation is being established
[91]. A recent report highlighted the role of Nup155 in
regulating translation of P21 which, a key downstream
effector of P53 response in liver cancer, thus regulating
P53 network [76]. Nup155 also emerged as an important
modulator of chromatin remodeling by interaction with
HDAC4 [77]. More recently, Nup155 has been shown to
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regulate non-coding RNA network mouse embryonic
stem cells (mESCs). Partial loss of Nup155 led to
reduction in abundance of miR290–295 cluster with
concomitant loss of pluripotency factors in mES cells
thus affecting pluripotency [78]. The involvement of a
single nucleoporin in a wide variety of signaling
networks
including
pluripotency
underscores
widespread functions. Our data show that NUP155 is not
only significantly upregulated in breast cancer but also
correlated with poor patient survival. It remains to be
seen if and how individual pathways regulated by
Nup155 converge onto the pathogenic phenotype in
breast cancer.
Another novel molecule that was identified through
our in silico analysis is SEC13. Although SEC13 is
generally associated with COPII vesicle for the
anterograde movement of molecules from ER to Golgi,
its location in the nuclear pore is well established where
it is a part of Nup107-160 subcomplex [37]. Additionally,
its nucleocytoplasmic shuttling of SEC13 is also
reported [79]. In the nucleus, it is also shown to bind
kinetochores [37]. Its multi-compartmental distribution
indicates a variety of possible functions. Our analysis
indicates that it is not only significantly upregulated,
but also correlates with poor patient survival, thus
warranting deeper exploration.
It is pertinent to note that majority of Nups were
upregulated in breast cancer patients (Figure 3). While
expression of most of them is correlated with poor
patient survival, thus pointing to their roles as
oncogenes, overexpression of some Nups correlated
with better over all patient survival. The Nups in this
category included Nup98, TPR and POM121L12. The
correlation between their overexpression and better
patient survival might provide a hint for their possible
tumor suppressor functions. Further studies are
required to realize their role in cell survival and
proliferation by using loss of function and gain of
function assays in cellular models.
As nucleoporins feed multiple arms of the cellular
physiology, it is challenging to identify what particular
altered functions might lead to tumorigenesis. Finding
the downstream effects is important as it provides an
opportunity to target the specific pathway for
therapeutic purpose. e.g. Importazole was used to
reduce tumorogenic potential in POM121 overexpressed
cells as it was mediated through interaction with
importin  [80]. However, individual Nups might have
role in the disease progression that is independent of
nuclear transport functions, e.g the role of Nup62 in
regulating gastric cancer metastasis by regulating
Wnt/-Catenin and TGF- signaling pathways [81]. In
such circumstances, individual Nups and/or the
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downstream pathways that are altered might have to be
unraveled for eventual targeting.
Although inhibitors for nuclear transport receptors are
relatively well studied in cancer, specific inhibitors for
Nups are equally promising in various malignancies
considering their massive deregulation, as exemplified
by the current study in breast cancer. The mutations in
Nup genes were represented in 50% of the breast cancer
patients in addition to deregulated expression
representing an important vulnerable point. The
repertoire of small molecules perturbing the nuclear
pore permeability by disrupting FG interactions is
limited to only trans1-2 cyclohexanediol (CHD) and
Pitstop2 [82, 83]. Despite their ability to compromise the
NPC permeability barrier effectively, their systemic
effects on the NPCs may hinder their use in
therapeutics. Design and synthesis of small molecules
targeting specific components of NPCs remains an
arduous task, albeit with potential to pave way for novel
therapeutic strategies in breast cancer.
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Supplementary Figure 1: A) Overall mutation frequency in the nucleoporins group in breast cancer. (B) Representation of
mutations in nucleoporin genes in different breast cancer subtypes.
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Supplementary Figure 2

Supplementary Figure 2: Nup genes without a significant correlation with patient survival. Overall patient survival shown by
Meier-Kaplan plots. X axis shows Overall survival percentage, and Y axis shows Months after the diagnosis. High expression group is
indicated by red, while the low expression group is shown by the black color. The patients (n=1402) were split by median. p-values
were determined using the Log-Rank test.
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